We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Shock Wave Device Helps Treat Diabetic Foot Ulcers

By HospiMedica International staff writers
Posted on 10 Jan 2018
Print article
Image: An extracorporeal shock wave system treats DFUs (Photo courtesy of Sanuwave).
Image: An extracorporeal shock wave system treats DFUs (Photo courtesy of Sanuwave).
A novel extracorporeal shock wave system uses pulses of energy in the shock wave spectrum to mechanically stimulate the diabetic foot ulcer (DFU).

The Sanuwave (Suwanee, GA, USA) Dermapace System is based on pulsed acoustic cellular expression (PACE) technology, which utilizes high-energy acoustic pressure waves to produce compressive and tensile stresses on cells and tissue structures in order to elicit a series of biological responses that increase tissue perfusion and arteriogenesis, disrupt biofilm, initiate pro-inflammatory responses, invoke cytokine and chemokine effects, growth factor upregulation, and angiogenesis. The result is a regeneration of tissues such as skin, musculoskeletal, and vascular structures.

The system is intended for the treatment of chronic, full-thickness DFUs with wound areas measuring no larger than 16 cm2, which extend through the epidermis, dermis, tendon, or capsule, but without bone exposure. During treatment, the dermaPACE device pulse applicator is gently applied to the wound surface; an audible “popping” sound is generated until treatment end. In general, only a few treatments lasting just a few minutes are needed; however, treatment time, as well as the overall number of treatments, depends on the wound condition.

“Not all wounds, nor all patients are the same; therefore, each wound is treated on an individual basis, based on the treating physician’s knowledge and the treatment options available. Due to its non-invasive nature, the dermaPACE System does not prevent the use of other treatment options,” said Kevin Richardson II, CEO and chairman of the Board of Sanuwave. “The dermaPACE system offers the ability to manage the DFUs chronicity, and is a powerful tool in the clinician’s arsenal to achieve wound closure.”

Diabetes patients often suffer from nerve and circulation problems in the feet, which reduce their perception of pain. The nerve pathways that ensure that weight is automatically transferred from one foot to the other during prolonged standing are disrupted, and as a result, diabetics do not notice that their toes, heels, or the balls of their feet are too heavily loaded. The foot receives no relief, and due to the neuropathy, pressure sores, DFUs, and infections may go unnoticed. Serious cases may even lead to amputation.

Related Links:
Sanuwave


Print article

Channels

Business

view channel
Illustration

Siemens to Acquire Varian Medical to Create Comprehensive Cancer Portfolio

Siemens Healthineers (Erlangen, Germany) has entered into an agreement to acquire Varian Medical Systems, Inc. (Palo Alto, CA, USA) that will lead to the creation of a global leader in healthcare with... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.